TY - JOUR
T1 - Transition from parenteral prostacyclins to selexipag
T2 - safety and feasibility in selected patients
AU - Aldweib, Nael
AU - Verlinden, Nathan J.
AU - Kassis-George, Hayah
AU - Raina, Amresh
N1 - Publisher Copyright:
© The Author(s) 2021.
PY - 2021
Y1 - 2021
N2 - There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting.
AB - There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting.
KW - pulmonary arterial hypertension
KW - pulmonary vasodilators
KW - the United States Registry to Evaluate Early and Long-term PAH disease management (REVEAL)
UR - http://www.scopus.com/inward/record.url?scp=85116785177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116785177&partnerID=8YFLogxK
U2 - 10.1177/20458940211036623
DO - 10.1177/20458940211036623
M3 - Article
AN - SCOPUS:85116785177
SN - 2045-8932
VL - 11
JO - Pulmonary Circulation
JF - Pulmonary Circulation
IS - 4
ER -